About Alkahest
Alkahest is a company based in San Carlos (United States) founded in 2014 was acquired by Grifols in September 2020. Alkahest has raised $41 million across 2 funding rounds from investors including Grifols. The company has 82 employees as of December 31, 2023. Alkahest offers products and services including AKST4290, AKST/GRF6019/6021, and AKST1210.
- Headquarter San Carlos, United States
- Employees 82 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alkahest, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alkahest
Alkahest offers a comprehensive portfolio of products and services, including AKST4290, AKST/GRF6019/6021, and AKST1210.
Drug candidate for Wet AMD and Parkinson's Disease treatment.
Targets Alzheimer's and Parkinson's with cognitive benefits.
Addresses cognitive impairment in end-stage renal disease.
People of Alkahest
Unlock access to complete
Unlock access to complete
Leadership Team
9 people
Scientific Team
7 people
Data Analysis and Operations Team
4 people
Legal and Compliance
3 people
Human Resources and Administration
3 people
Product Management Team
1 people
Software Development Team
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of Alkahest
Alkahest has successfully raised a total of $41M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $37.5 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alkahest
Alkahest has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Grifols.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Plasma-derived therapies are developed to treat multiple diseases.
|
Locked | Locked | Locked |
Investor details for Alkahest
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alkahest
Investment portfolio details for Alkahest
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alkahest
Detailed financials for Alkahest
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alkahest Comparisons
Peer comparison for Alkahest
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alkahest
Detailed competitors of Alkahest
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alkahest
Complete news archive for Alkahest
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alkahest
Alkahest was founded in 2014.
Alkahest is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Karoly Nikolich is the current CEO of Alkahest.
Alkahest is a funded company, having raised a total of $41M across 2 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Alkahest is 82.
Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline. Its research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimers disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Grifols made an investment of 37.5 million for a 45 stake in Alkahest along with another 12.5 million RD and certain commercial rights.
Alkahest offers AKST4290, AKST/GRF6019/6021, and AKST1210.
Alkahest has 1 investor. Key investors include Grifols.